Daniel Nettersheim (D Nettersheim)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 24

Top Venues

British journal of cancer

Journal of cellular and molecular medicine

Molecular medicine (Cambridge, Mass.)

Cancers

Heinrich-Heine-Universität Düsseldorf

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Heinrich-Heine-Universität Düsseldorf May 01 2018

Germany

Professor ‚Translational Urooncology‘ :: University Medical School, Clinic of Urology, Urological Research Lab

Rheinische Friedrich Wilhelms Universitat Bonn - Mar 01 2018

Germany

DFG "eigene Stelle" :: University Hospital, Institute of Pathology, Department of Developmental Pathology

Rheinische Friedrich Wilhelms Universitat Bonn Apr 01 2013 - Apr 01 2015

Germany

Junior research group leader :: University Hospital, Institute of Pathology, Department of Developmental Pathology

Rheinische Friedrich Wilhelms Universitat Bonn Oct 01 2010 - Apr 01 2013

Germany

Lab Scientist / PostDoc :: University Hospital, Institute of Pathology, Departement of Developmental Pathology

Rheinische Friedrich Wilhelms Universität Bonn Oct 01 2006 - Oct 01 2010

Germany

Lab Scientist / PhD student :: University Hospital, Institute of Pathology, Department of Developmental Pathology

Hochschule Bonn-Rhein-Sieg - Campus Rheinbach May 01 2005 - Jun 01 2006

Germany

Staff Scientist

Publications

Alexander Fichtner, Daniel Nettersheim, Felix Bremmer
Pathogenesis and pathobiology of testicular germ cell tumours: a view from a developmental biological perspective with guidelines for pathological diagnostics. Histopathology (2024)
Kai Funke, Ulf Einsfelder, Aylin Hansen, Lena Arévalo, Simon Schneider, Daniel Nettersheim, Valentin Stein, Hubert Schorle
Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours. British journal of cancer (2023)
Felix Bremmer, Pailin Pongratanakul, Margaretha Skowron, Yue Che, Annika Richter, Stefan Küffer, Kirsten Reuter-Jessen, Hanibal Bohnenberger, Stella Pauls, Catena Kresbach, Ulrich Schüller, Kai Stühler, Philipp Ströbel, Peter Albers, Daniel Nettersheim
Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets. British journal of cancer (2023)
Christian Söhngen, David J Thomas, Margaretha A Skowron, Felix Bremmer, Markus Eckstein, Anja Stefanski, Marc D Driessen, Gamal A Wakileh, Kai Stühler, Peter Altevogt, Dan Theodorescu, Rüdiger Klapdor, Axel Schambach, Daniel Nettersheim
CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners. The FEBS journal (2023)
Margaretha A Skowron, Mara Kotthoff, Felix Bremmer, Katja Ruhnke, Fatma Parmaksiz, Annika Richter, Stefan Küffer, Kirsten Reuter-Jessen, Stella Pauls, Anja Stefanski, Philipp Ströbel, Kai Stühler, Daniel Nettersheim
Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options. Molecular medicine (Cambridge, Mass.) 29 (1) (2023)
Felix Bremmer, Lena Lubk, Philipp Stroebel, Daniel Nettersheim
Updating germ cell tumour pathogenesis - the ability of seminomas for FOXA2-driven extra-embryonic differentiation. Histopathology (2023)
Margaretha A Skowron, Mara Kotthoff, Felix Bremmer, Katja Ruhnke, Fatma Parmaksiz, Annika Richter, Stefan Küffer, Kirsten Reuter-Jessen, Stella Pauls, Anja Stefanski, Philipp Ströbel, Kai Stühler, Daniel Nettersheim
Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options. Molecular medicine (Cambridge, Mass.) 29 (1) (2023)
Margaretha A Skowron, Mara Kotthoff, Felix Bremmer, Katja Ruhnke, Fatma Parmaksiz, Annika Richter, Stefan Küffer, Kirsten Reuter-Jessen, Stella Pauls, Anja Stefanski, Philipp Ströbel, Kai Stühler, Daniel Nettersheim
Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options. Molecular medicine (Cambridge, Mass.) 29 (1) (2023)
Aaron Burmeister, Alexa Stephan, Leandro A Alves Avelar, Melanie R Müller, Andrea Seiwert, Stefan Höfmann, Fabian Fischer, Hector Torres-Gomez, Michèle Janine Hoffmann, Guenter Niegisch, Felix Bremmer, Patrick Petzsch, Karl Köhrer, Peter Albers, Thomas Kurz, Margaretha A Skowron, Daniel Nettersheim
Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies. Molecular cancer therapeutics 21 (11) (2022)
Margaretha A Skowron, Katharina Eul, Alexa Stephan, Gillian F Ludwig, Gamal A Wakileh, Arthur Bister, Christian Söhngen, Katharina Raba, Patrick Petzsch, Gereon Poschmann, Edmund Osei Kuffour, Daniel Degrandi, Shafaqat Ali, Constanze Wiek, Helmut Hanenberg, Carsten Münk, Kai Stühler, Karl Köhrer, Elvira Mass, Daniel Nettersheim
Profiling the 3D interaction between germ cell tumors and microenvironmental cells at the transcriptome and secretome level. Molecular oncology 16 (17) (2022)
Melanie R Müller, Aaron Burmeister, Margaretha A Skowron, Alexa Stephan, Felix Bremmer, Gamal A Wakileh, Patrick Petzsch, Karl Köhrer, Peter Albers, Daniel Nettersheim
Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights. Clinical epigenetics 14 (1) (2022)
Vera Miranda-Gonçalves, João Lobo, Catarina Guimarães-Teixeira, Daniela Barros-Silva, Rita Guimarães, Mariana Cantante, Isaac Braga, Joaquina Maurício, Christoph Oing, Friedemann Honecker, Daniel Nettersheim, Leendert H J Looijenga, Rui M Henrique, Carmen Jerónimo
The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. Journal of experimental & clinical cancer research : CR 40 (1) (2021)
Wasco Wruck, Felix Bremmer, Mara Kotthoff, Alexander Fichtner, Margaretha A Skowron, Stefan Schönberger, Gabriele Calaminus, Christian Vokuhl, David Pfister, Axel Heidenreich, Peter Albers, James Adjaye, Daniel Nettersheim
The pioneer and differentiation factor FOXA2 is a key driver of yolk-sac tumour formation and a new biomarker for paediatric and adult yolk-sac tumours. Journal of cellular and molecular medicine 25 (3) (2021)
Margaretha A Skowron, Teresa K Becker, Lukas Kurz, Sina Jostes, Felix Bremmer, Florian Fronhoffs, Kai Funke, Gamal A Wakileh, Melanie R Müller, Aaron Burmeister, Thomas Lenz, Anja Stefanski, Kai Stühler, Patrick Petzsch, Karl Köhrer, Peter Altevogt, Peter Albers, Glen Kristiansen, Hubert Schorle, Daniel Nettersheim
The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas. Molecular oncology (2021)
Margaretha A Skowron, Marieke Vermeulen, Anna Winkelhausen, Teresa K Becker, Felix Bremmer, Patrick Petzsch, Stefan Schönberger, Gabriele Calaminus, Karl Köhrer, Peter Albers, Daniel Nettersheim
CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms. British journal of cancer 123 (3) (2020)
Lukas Kurz, Alissa Miklyaeva, Margaretha A Skowron, Nina Overbeck, Gereon Poschmann, Teresa Becker, Katharina Eul, Thomas Kurz, Stefan Schönberger, Gabriele Calaminus, Kai Stühler, Emily Dykhuizen, Peter Albers, Daniel Nettersheim
ARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 while ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition. Cancers 12 (4) (2020)
Harald Welter, Carola Herrmann, Fröhlich Thomas, Florian Flenkenthaler, Katja Eubler, Hubert Schorle, Daniel Nettersheim, Artur Mayerhofer, Annette Müller-Taubenberger
Filamin A Orchestrates Cytoskeletal Structure, Cell Migration and Stem Cell Characteristics in Human Seminoma TCam-2 Cells. Cells 9 (12) (2020)
Stefan Schönberger, Daniela Kraft, Daniel Nettersheim, Hubert Schorle, Anna Casati, Rogerio B Craveiro, Mahsa Mir Mohseni, Gabriele Calaminus, Dagmar Dilloo
Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines. Cancers 12 (5) (2020)
Daniel Nettersheim, Saskia Vadder, Sina Jostes, Alena Heimsoeth, Hubert Schorle
TCam-2 Cells Deficient for SOX2 and FOXA2 Are Blocked in Differentiation and Maintain a Seminoma-Like Cell Fate In Vivo. Cancers 11 (5) (2019)
Sina V Jostes, Martin Fellermeyer, Lena Arévalo, Gina E Merges, Glen Kristiansen, Daniel Nettersheim, Hubert Schorle
Unique and redundant roles of SOX2 and SOX17 in regulating the germ cell tumor fate. International journal of cancer 146 (6) (2019)
Christoph Oing, Margaretha A Skowron, C Bokemeyer, Daniel Nettersheim
Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations. Andrology 7 (4) (2019)
Daniel Nettersheim, D Berger, S Jostes, G Kristiansen, G Lochnit, Hubert Schorle
N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, erasers, and readers. Andrology 7 (4) (2019)
Daniel Nettersheim, Daniel Berger, Sina Jostes, Margaretha Skowron, Hubert Schorle
Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors. Journal of cellular and molecular medicine 23 (1) (2018)
Stefan Schönberger, Cornelius van Beekum, Barbara Götz, Daniel Nettersheim, Hubert Schorle, Dominik T Schneider, Anna Casati, Rogerio B Craveiro, Gabriele Calaminus, Dagmar Dilloo
Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines. Journal of cellular and molecular medicine 22 (1) (2017)

Daniel Nettersheim.css-eqlu8i{font-size:small;padding-left:4px;} (D Nettersheim)

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel Nettersheim (D Nettersheim)